Guna, Alina
Page, Katharine R.
Replogle, Joseph M.
Esantsi, Theodore K.
Wang, Maxine L.
Weissman, Jonathan S.
Voorhees, Rebecca M.
Funding for this research was provided by:
Rosen Family fellowship
Arie Jan Haagen-Smit Fellowship
NIH F31 Ruth L. Kirchstein National Research Service Award (NS115380)
Center for Genome Editing and Recording (2RM1 HG009490-06)
Human Frontier Science Program (2019L/LT000858)
Howard Hughes Medical Institute
Heritage Medical Research Institute
NIH’s National Institute of General Medical Sciences (DP2GM137412)
Article History
Received: 20 June 2023
Accepted: 19 October 2023
First Online: 30 October 2023
Declarations
:
: Not applicable.
: Not applicable.
: JMR consults for Maze Therapeutics and Waypoint Bio. JSW declares outside interest in 5 AM Venture, Amgen, Chroma Medicine, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics, and Third Rock Ventures. RMV is a consultant and equity holder in Gate Bioscience. The Regents of the University of California with JSW as inventor have filed patent applications related to CRISPRi/a screening and Perturb-seq. JSW is an inventor on US Patent 11,254,933 related to CRISPRi/a screening. No potential conflicts of interests were declared by the other authors.